Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in patients with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC
• Treatments: QS 21; Saponin QA-21V1

Criteria

Inclusion Criteria:

• Diagnosis of probable Alzheimer's Disease with Mini-Mental State Examination (MMSE) score of 16-26 (except Germany: 21-26)

• Brain MRI consistent with Alzheimer Disease

• Concurent use of Chloniesterase inhibitor or memantine allowed if stable

• Other inclusion criteria apply

Exclusion Criteria:

• Significant Neurological Disease other than Alzheimer's disease

• Major psychiatric disorder

• Contraindication to undergo brain MRI

• Clinically significant systemic illness

• Other exclusion criteria apply